September 9, 2013

High ‘Cholera Sell’? Vouching for Paxvax’s Phase III Strategy

Source: BioWorld Today
Publication Date: September 9, 2013
Visit Source

Paxvax Inc.’s just-begun Phase III effort with PXVX0200 could lead to the first cholera vaccine approved for marketing in the U.S., and the company could become the first to gauge the resale value of the FDA’s priority review voucher (PRV), an incentive put in place six years ago to boost work against neglected tropical diseases.